Imperial College London


Faculty of MedicineSchool of Public Health

Clinical Fellow







Medical SchoolSt Mary's Campus




Selected Publications

Journal Articles

Daunt A, Perez-Guzman PN, Liew F, et al., 2020, Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease, Journal of Infection, Vol:81, ISSN:0163-4453, Pages:666-668

Perez Guzman PN, Daunt A, Mukherjee S, et al., 2020, Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study, Clinical Infectious Diseases, ISSN:1058-4838

Walker PGT, Whittaker C, Watson OJ, et al., 2020, The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries, Science, Vol:369, ISSN:0036-8075, Pages:413-422

Nayagam AS, Chan P, Zhao K, et al., 2020, Investment case for a comprehensive package of interventions against Hepatitis B in China; applied modelling to help national strategy planning, Clinical Infectious Diseases, ISSN:1058-4838

Nayagam S, Shimakawa Y, Lemoine M, 2020, Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world?, Journal of Viral Hepatitis, Vol:27, ISSN:1345-2533, Pages:342-349

Heffernan A, Cooke G, Nayagam S, et al., 2019, Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, The Lancet, Vol:393, ISSN:0140-6736, Pages:1319-1329

Cooke GS, Andrieux-Meyer I, Applegate TL, et al., 2019, Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184

Yusuke S, Njie R, Ndow G, et al., 2018, Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa, Journal of Hepatology, Vol:69, ISSN:0168-8278, Pages:776-784

Hecht R, Hiebert L, Spearman WC, et al., 2018, The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Health Policy and Planning, Vol:33, ISSN:1460-2237, Pages:528-538

Nayagam S, Thursz M, Sicuri E, et al., 2016, Requirements for global elimination of hepatitis B: a modelling study., Lancet Infectious Diseases, Vol:16, ISSN:1473-3099, Pages:1399-1408

Lemoine MN, Shimakawa Y, Njie R, et al., 2016, Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study, Lancet Global Health, Vol:4, ISSN:2214-109X, Pages:e559-e567

Nayagam S, Conteh L, Sicuri E, et al., 2016, Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis, Lancet Global Health, Vol:4, ISSN:2214-109X, Pages:e568-e578

More Publications